news

on august 29, yifeng pharmacy, a large-scale national pharmaceutical retail chain (a chain pharmacy listed on the shanghai stock exchange main board in china), released its 2024 semi-annual report. during the reporting period, yifeng's total revenue exceeded 10 billion yuan, handing in a brilliant "mid-term report" to the big health industry!

2024 half-year revenue is 11.76 billion yuan, and asset scale continues to grow

currently, against the backdrop of global economic recovery, china's medical and health industry is showing an overall upward trend.according to the 2024 semi-annual report released by yifeng, its growth rate is exactly proportional to the favorable environment. data shows that yifeng pharmacy achieved operating income of 11.762 billion yuan during the reporting period, a year-on-year increase of 9.86%. the net profit attributable to shareholders of listed companies was 798 million yuan, and the non-net profit was 786 million yuan, an increase of 13.13% and 15.77% respectively over the same period last year. both operating income and operating profit have achieved steady growth, with strong market competitiveness. in terms of asset scale, yifeng has also achieved significant and sustained growth. as of june 30, 2024, the company's total assets were 26.43 billion yuan, an increase of 9.53% from the end of the previous year.

according to the "white paper on the development of china's medical and healthcare industry in 2024", in 2023, the population of china over 65 years old will reach 216.8 million, accounting for 15.4% of the total population. in a moderately aging society, medical needs will accelerate the evolution towards "health-centered". as an important part of the medical and healthcare industry, the social value of retail pharmacies needs to be "re-seen" to meet more massive health needs. in this context, yifeng pharmacy has cultivated new growth momentum for pharmacies through its superior profitability, refined operational management capabilities, and the construction of an omni-channel new pharmaceutical retail system, contributing to the prosperity and development of the medical and healthcare industry.

96.16 million members have been registered, and refined operations are recognized

yifeng actively responds to the relevant requirements of the "healthy china 2030" plan, helping to build a modern medical distribution network covering urban and rural areas and improving the drug supply guarantee capabilities at the grassroots and remote areas.

yifeng has long adhered to the development strategy of "regional focus and steady expansion", with the market expansion goal of "consolidating central, southern, eastern and northern china and expanding the national market". through the vertical integration layout of "new opening + mergers and acquisitions + franchising", a multi-level store network layout has been formed to effectively and deeply guarantee the people's demand for medicines. according to the 2024 semi-annual report, during the reporting period, the total number of yifeng stores reached 14,736 (including 3,426 franchise stores); 9,984 pharmacies have obtained various "medical insurance designated retail pharmacies" qualifications, accounting for 88.28% of the total number of self-operated stores.

in the era of "involution", "ensuring customer flow" is the first priority for retail pharmacies. yifeng has continuously consolidated its membership base through refined operations, improved its health management service capabilities throughout the life cycle, and "takes responsibility" for its members. according to the 2024 semi-annual report, during the reporting period, yifeng had 96.16 million registered members, accounting for 77% of the overall sales.

the dual-engine strategy resulted in online revenue of 1.818 billion yuan

the rapid development of internet technology and new media has provided a huge market space for the diversified and omni-channel development of retail pharmacies. yifeng has seized the dividends of the times and adopted a model of online and offline integrated development to achieve omni-channel incremental development.

especially in terms of online, yifeng adopts the "o2o+b2c" dual-engine strategy to create a digital, efficient and high-quality service system, improve operational efficiency, reduce fulfillment costs, bring greater profits to the overall business, and "lead" the entire industry. yifeng's 2024 semi-annual report shows that during the reporting period, the internet business achieved sales revenue of 1.096 billion yuan, of which o2o sales revenue was 878 million yuan, a year-on-year increase of 26.33%; b2c sales revenue was 218 million yuan, a year-on-year increase of 0.46%.

pharmacies are the traffic entrance for community health and the second terminal for drug sales. they need to shoulder the mission of the times, grasp new user needs, and achieve innovative upgrades. yifeng accelerates the integrated development of "internet + medical health" to give consumers more choices and help build a good new pharmaceutical retail ecosystem.

in the 21st century, china's medical and health industry is "accelerating" at an unprecedented speed, empowering and improving social progress and economic growth. in this process, industry forces such as yifeng pharmacy are constantly optimizing and improving their professional capabilities and service levels, strengthening industry self-discipline, improving core capabilities, and jointly promoting the development of the industry to a new stage!

(source: financial information)

for more exciting information, please download the "jimu news" client from the application market. please do not reprint without authorization. you are welcome to provide news clues, and you will be paid once adopted.